Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
In this trial, we will evaluate the feasibility, toxicity, and effectiveness ibritumomab
tiuxetan, when incorporated into combination first-line treatment for follicular lymphoma.
Addition of the ibritumomab tiuxetan to our previously evaluated, well tolerated combination
of rituximab and short course chemotherapy will allow the use of additional active agent with
a unique mechanism of cytotoxicity. In addition, "debulking" of lymphoma prior to 90Y Zevalin
administration may minimize the myelotoxicity of this agent.